Ramipril Dosing and Monitoring Guidelines

Heart Failure Dosing and Titration

Initiate ramipril at 1.25–2.5 mg once daily in patients with chronic heart failure and titrate to a maintenance dose of 2.5–5 mg twice daily, aiming for 5 mg twice daily as used in large outcome trials. 1, 2
Titration protocol: start the low dose for one week, then check serum potassium and creatinine 5–7 days after each dose increase; re‑check electrolytes every 5–7 days until values are stable, and continue dose escalation to the maintenance range proven effective in major trials. 1, 2
After each dose increment, monitor blood pressure, renal function, and electrolytes 1–2 weeks later, again at 3 months, and subsequently at 6‑month intervals. 1, 2

Begin ramipril at 2.5 mg twice daily in patients with recent myocardial infarction and left‑ventricular dysfunction, and titrate to a target of 5 mg twice daily. 3, 4, 5
Administer the first dose within the first 24 hours after STEMI in patients with anterior infarction, clinical heart failure, or an ejection fraction ≤ 0.40, provided no contraindications exist. 3, 4, 5

For patients with creatinine clearance < 30 mL/min, start ramipril at 1.25 mg once daily; the total daily dose must not exceed 5 mg. 8, 9
Closely monitor serum creatinine after initiation; discontinue ramipril if renal function deteriorates substantially. 1, 2, 6, 7

Use caution in patients older than 85 years, especially those with symptomatic orthostatic hypotension or moderate‑to‑severe frailty; consider lower starting doses and close hemodynamic monitoring. 10

Reduce or withhold diuretics for at least 24 hours before starting ramipril in patients with low baseline blood pressure. 1, 2, 6, 7
Prefer evening (supine) initiation to lessen the risk of symptomatic hypotension; if started in the morning, provide several hours of supervised blood pressure monitoring, particularly in patients with renal dysfunction or low baseline pressure. 1, 2, 6, 7
Avoid ramipril initiation when systolic blood pressure is < 90 mm Hg or when it is > 30 mm Hg below the patient’s usual baseline. 3, 4, 5

Contraindicated in patients with bilateral renal artery stenosis, a history of angio‑edema with prior ACE‑inhibitor therapy, or pregnancy. 1, 2, 6, 11
During initiation, avoid concomitant use of potassium‑sparing diuretics, NSAIDs, and COX‑2 inhibitors. 1, 2, 6, 7
Actively monitor for hypotension, worsening renal function, and hyper‑kalemia after each dose change. 3, 4, 5
Review and, if necessary, adjust the dose of diuretics and vasodilators before starting ramipril to minimize adverse hemodynamic effects. 1, 2, 6, 7

Do not combine ramipril with an ARB and an aldosterone antagonist (triple therapy) because it is associated with increased harm. 11
Angio‑edema occurs in < 1 % of patients and is more frequent in Black patients; if it develops, ACE inhibitors should be avoided for the patient’s lifetime. 11
Up to 20 % of patients may develop an ACE‑inhibitor‑induced cough; clinicians should counsel patients regarding this possibility. 11